肿瘤和宿主溶质载体对临床药物反应的贡献。
Contribution of tumoral and host solute carriers to clinical drug response.
机构信息
Department of Pharmaceutical Sciences, St Jude Children's Research Hospital, Memphis, TN 38105, USA.
出版信息
Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20. doi: 10.1016/j.drup.2012.01.009. Epub 2012 Mar 28.
Abstract
Members of the solute carrier family of transporters are responsible for the cellular uptake of a broad range of endogenous compounds and xenobiotics in multiple tissues. Several of these solute carriers are known to be expressed in cancer cells or cancer cell lines, and decreased cellular uptake of drugs potentially contributes to the development of resistance. As result, the expression levels of these proteins in humans have important consequences for an individual's susceptibility to certain drug-induced side effects, interactions, and treatment efficacy. In this review article, we provide an update of this rapidly emerging field, with specific emphasis on the direct contribution of solute carriers to anticancer drug uptake in tumors, the role of these carriers in regulation of anticancer drug disposition, and recent advances in attempts to evaluate these proteins as therapeutic targets.
摘要
溶质载体家族转运体的成员负责在多种组织中摄取广泛的内源性化合物和外源性毒物。这些溶质载体中有几种已知在癌细胞或癌细胞系中表达，细胞对药物的摄取减少可能导致耐药性的发展。因此，这些蛋白质在人体内的表达水平对个体对某些药物引起的副作用、相互作用和治疗效果的易感性有重要影响。在这篇综述文章中，我们提供了这个快速发展领域的最新信息，特别强调了溶质载体对肿瘤中抗癌药物摄取的直接贡献、这些载体在抗癌药物处置中的作用，以及最近尝试将这些蛋白质作为治疗靶点的进展。
相似文献
1
Contribution of tumoral and host solute carriers to clinical drug response.肿瘤和宿主溶质载体对临床药物反应的贡献。
Drug Resist Updat. 2012 Feb-Apr;15(1-2):5-20. doi: 10.1016/j.drup.2012.01.009. Epub 2012 Mar 28.
2
The role of OATP1B1 and OATP1B3 transporter polymorphisms in drug disposition and response to anticancer drugs: a review of the recent literature.OATP1B1 和 OATP1B3 转运体多态性在药物处置和抗癌药物反应中的作用：对近期文献的综述。
Expert Opin Drug Metab Toxicol. 2022 Jul-Aug;18(7-8):459-468. doi: 10.1080/17425255.2022.2113380. Epub 2022 Aug 30.
3
Solute Carrier Transportome in Chemotherapy-Induced Adverse Drug Reactions.溶质载体转运组在化疗药物不良反应中的作用。
Rev Physiol Biochem Pharmacol. 2022;183:177-215. doi: 10.1007/112_2020_30.
4
Membrane drug transporters in cancer: From chemoresistance mechanism to therapeutic strategies.癌症中的膜药物转运体：从化疗耐药机制到治疗策略。
Biochim Biophys Acta Rev Cancer. 2025 Apr;1880(2):189272. doi: 10.1016/j.bbcan.2025.189272. Epub 2025 Jan 23.
5
Contribution of membrane transporters to chemotherapy-induced cardiotoxicity.膜转运蛋白在化疗所致心脏毒性中的作用
Basic Clin Pharmacol Toxicol. 2022 Jan;130 Suppl 1:36-47. doi: 10.1111/bcpt.13635. Epub 2021 Jul 21.
6
Influence of multidrug resistance and drug transport proteins on chemotherapy drug metabolism.多药耐药性和药物转运蛋白对化疗药物代谢的影响。
Expert Opin Drug Metab Toxicol. 2015 May;11(5):795-809. doi: 10.1517/17425255.2015.1028356. Epub 2015 Apr 2.
7
USP32 confers cancer cell resistance to YM155 via promoting ER-associated degradation of solute carrier protein SLC35F2.USP32 通过促进溶质载体蛋白 SLC35F2 的 ER 相关降解赋予癌细胞对 YM155 的耐药性。
Theranostics. 2021 Sep 27;11(20):9752-9771. doi: 10.7150/thno.63806. eCollection 2021.
8
Apical ABC transporters and cancer chemotherapeutic drug disposition.顶端 ABC 转运蛋白与癌症化疗药物处置。
Adv Cancer Res. 2015;125:1-41. doi: 10.1016/bs.acr.2014.10.001. Epub 2015 Jan 8.
9
Emerging roles of metal solute carriers in cancer mechanisms and treatment.金属溶质载体在癌症机制与治疗中的新作用
Biopharm Drug Dispos. 2014 Nov;35(8):450-62. doi: 10.1002/bdd.1903. Epub 2014 Sep 5.
10
Membrane transporters as determinants of the pharmacology of platinum anticancer drugs.膜转运蛋白作为铂类抗癌药物药理学的决定因素。
Curr Cancer Drug Targets. 2012 Oct;12(8):962-86. doi: 10.2174/156800912803251199.
引用本文的文献
1
Targeting Lipid Transport Pathways: A New Frontier in Colorectal Cancer Therapy.靶向脂质转运途径：结直肠癌治疗的新前沿
Dig Dis Sci. 2025 Jul 24. doi: 10.1007/s10620-025-09214-5.
2
Expression status of p53 and organic cation transporter 1 is correlated with poor response to preoperative chemotherapy in esophageal squamous cell carcinoma.p53 和有机阳离子转运蛋白 1 的表达状态与食管鳞癌对术前化疗的不良反应相关。
World J Surg Oncol. 2022 Apr 1;20(1):105. doi: 10.1186/s12957-022-02571-9.
3
Solute carrier family 12 member 8 (SLC12A8) is a potential biomarker and related to tumor immune cell infiltration in bladder cancer.溶质载体家族 12 成员 8（SLC12A8）是膀胱癌的一个潜在的生物标志物，与肿瘤免疫细胞浸润有关。
Bioengineered. 2021 Dec;12(1):4946-4961. doi: 10.1080/21655979.2021.1962485.
4
The Expression Profiles of ADME Genes in Human Cancers and Their Associations with Clinical Outcomes.人类癌症中药物代谢及药物处置相关基因的表达谱及其与临床结局的关联。
Cancers (Basel). 2020 Nov 13;12(11):3369. doi: 10.3390/cancers12113369.
5
Interferon-beta enhances sensitivity to gemcitabine in pancreatic cancer.干扰素-β增强胰腺癌对吉西他滨的敏感性。
BMC Cancer. 2020 Sep 23;20(1):913. doi: 10.1186/s12885-020-07420-0.
6
Modeling cancer drug response through drug-specific informative genes.通过药物特异性信息基因来模拟癌症药物反应。
Sci Rep. 2019 Oct 23;9(1):15222. doi: 10.1038/s41598-019-50720-0.
7
Harnessing Solute Carrier Transporters for Precision Oncology.利用溶质载体转运蛋白实现精准肿瘤学
Molecules. 2017 Mar 28;22(4):539. doi: 10.3390/molecules22040539.
8
Inhibitory effects of chemotherapeutics on human organic anion transporter hOAT4.化疗药物对人类有机阴离子转运体hOAT4的抑制作用。
Int J Biochem Mol Biol. 2016 Jun 1;7(1):11-8. eCollection 2016.
9
Organic cation transporter 2 for predicting cisplatin-based neoadjuvant chemotherapy response in gastric cancer.用于预测胃癌中基于顺铂的新辅助化疗反应的有机阳离子转运体2
Am J Cancer Res. 2015 Jun 15;5(7):2285-93. eCollection 2015.
10
Impact of Expression Levels of Platinum-uptake Transporters Copper Transporter 1 and Organic Cation Transporter 2 on Resistance to Anthracycline/Taxane-based Chemotherapy in Triple-negative Breast Cancer.铂摄取转运蛋白铜转运蛋白1和有机阳离子转运蛋白2的表达水平对三阴性乳腺癌蒽环类/紫杉类化疗耐药性的影响
Breast Cancer (Auckl). 2015 Aug 4;9:49-57. doi: 10.4137/BCBCR.S27534. eCollection 2015.
本文引用的文献
1
Release of intracellular calcium primes chronic myeloid leukaemia cells for tyrosine kinase inhibitor-induced apoptosis.细胞内钙离子释放使慢性髓性白血病细胞对酪氨酸激酶抑制剂诱导的细胞凋亡敏感。
Leukemia. 2012 Mar;26(3):490-8. doi: 10.1038/leu.2011.231. Epub 2011 Sep 2.
2
Oral drug delivery utilizing intestinal OATP transporters.利用肠道 OATP 转运体的口服药物递送。
Adv Drug Deliv Rev. 2012 May 1;64(6):508-14. doi: 10.1016/j.addr.2011.07.007. Epub 2011 Jul 30.
3
The antiepileptic drugs phenobarbital and carbamazepine reduce transport of methotrexate in rat choroid plexus by down-regulation of the reduced folate carrier.抗癫痫药物苯巴比妥和卡马西平通过下调还原叶酸载体减少了脑膜瘤脉络丛中甲氨蝶呤的转运。
Mol Pharmacol. 2011 Oct;80(4):621-9. doi: 10.1124/mol.111.072421. Epub 2011 Jul 7.
4
Expression of organic anion-transporting polypeptides 1B1 and 1B3 in ovarian cancer cells: relevance for paclitaxel transport.有机阴离子转运多肽 1B1 和 1B3 在卵巢癌细胞中的表达：与紫杉醇转运的相关性。
Biomed Pharmacother. 2011 Sep;65(6):417-26. doi: 10.1016/j.biopha.2011.04.031. Epub 2011 Jun 12.
5
Gemcitabine chemotherapy for the treatment of metastatic bladder carcinoma.吉西他滨化疗治疗转移性膀胱癌。
BJU Int. 2011 Jul;108(2):168-79. doi: 10.1111/j.1464-410X.2011.10341.x.
6
Carboplatin dosing in ovarian cancer: problems and pitfalls.卵巢癌中的卡铂给药：问题与陷阱。
Int J Gynecol Cancer. 2011 Oct;21(7):1213-8. doi: 10.1097/IGC.0b013e31822127ad.
7
Organic anion transporting polypeptide 1B3 (OATP1B3) is overexpressed in colorectal tumors and is a predictor of clinical outcome.有机阴离子转运多肽1B3（OATP1B3）在结直肠癌肿瘤中过表达，是临床预后的一个预测指标。
Clin Exp Gastroenterol. 2008;1:1-7. doi: 10.2147/ceg.s3743. Epub 2008 Nov 2.
8
Pharmacokinetic impact of SLCO1A2 polymorphisms on imatinib disposition in patients with chronic myeloid leukemia.SLCO1A2 多态性对慢性髓性白血病患者伊马替尼处置的药代动力学影响。
Clin Pharmacol Ther. 2011 Jul;90(1):157-63. doi: 10.1038/clpt.2011.102. Epub 2011 Jun 1.
9
Induction chemotherapy with paclitaxel, ifosfamide, and cisplatin followed by concurrent chemoradiotherapy for unresectable locally advanced head and neck cancer.对于不可切除的局部晚期头颈癌，采用紫杉醇、异环磷酰胺和顺铂进行诱导化疗，随后进行同步放化疗。
Biomed Imaging Interv J. 2010 Jul-Sep;6(3):e23. doi: 10.2349/biij.6.3.e23. Epub 2010 Jul 1.
10
Oxaliplatin transport mediated by organic cation/carnitine transporters OCTN1 and OCTN2 in overexpressing human embryonic kidney 293 cells and rat dorsal root ganglion neurons.OCTN1 和 OCTN2 介导的奥沙利铂在过表达人胚肾 293 细胞和大鼠背根神经节神经元中的转运。
J Pharmacol Exp Ther. 2011 Aug;338(2):537-47. doi: 10.1124/jpet.111.181297. Epub 2011 May 23.
Zotero 插件